Background This study was carried out by the National Cancer Institute at Cairo University to look at the characteristics of the tumours, the specifics of the surgery, and the survival rates of cases of surgically resected stomach cancer. Materials and methods: Retrospective analysis of patients with stomach cancer who had applied to our clinic was done. The patients' age and gender, primary site, histological characteristics, TNM stage, treatment, oncological treatment modalities, and survival results were examined. Results: With a male to female ratio of 2.19, the trial included 83 individuals with a confirmed diagnosis of stomach cancer. 54.7 years old was the average age. The typical tumour size was 4 cm. Regarding the site of the tumor, it was distal in 59 (71.1 %) whereas proximal in 24 (28.9 %). Distal gastrectomy was done for 48 (57.8%) individuals while total gastrectomy while proximal gastrectomy were done for 27 (32.5%), 8 (9.6%) individuals respectively. Fifty (60.2%) individuals were subjected to Roux en y as a method of reconstruction while 33 (39.8%) individuals underwent Billroth II reconstruction. The majority of the tumours (80.72%) were T3 in size. T1, T2, and T4 tumours were comparatively rare. 51.8% of individuals (51.8%) had nodal disease that was positive. 39.75% of individuals had perineural invasion and lymph vascular invasion. Only one patient had grade 1 tumours, 44 (53%) had grade 2 tumours, and 38 (45.8%) had grade 3 tumours. All patients had negative resection margins (R0). The overall complication rate was 39%, and the median period of hospitalisation was 9 days. Neoadjuvant therapy was given for 40 (48.2%) individual and 51(61.44%) individuals received adjuvant treatment. The 5-year overall survival was 41.7% while the 5-year disease-free survival rate was 22.4. In univariate and multivariate assessment adjuvant treatment was the only independent predictor of survival. Conclusions: This study revealed that the survival outcome of surgically resected gastric cancer was better among patients who received adjuvant therapy.